Michigan-based Memorial Healthcare: First in U.S. to use new Neurofilament Light Chain technology for multiple sclerosis patients

Michigan-based Memorial Healthcare: First in U.S. to use new Neurofilament Light Chain technology for multiple sclerosis patients

Publication date: Sep 11, 2019

OWOSSO, Mich. , Sept. 10, 2019 /PRNewswire/ — The Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, and its Chief of Neurology, Rany Aburashed, D. O., are the first in the U. S. to use Neurofilament Light Chain testing prospectively for patients with multiple sclerosis.

The impact of NfL for patients with Multiple Sclerosis Neurofilament light chain is a polypeptide that provides the structural framework and support to nerve cells.

As the first U. S. hospital to actively research NfL testing in real world patients with multiple sclerosis, Memorial Healthcare is paving the way for future treatment of MS. “A patient’s presentation, degree of disability and symptoms all make up a unique fingerprint to their disease,” said Dr. Aburashed.

“My primary goal here at Memorial is to create an environment that is conducive and attractive for health care providers to practice their trade at the highest level, and an environment where openness and collaboration exists,” said Brian Long, FACHE, president and CEO of Memorial Healthcare.

In addition to its investment in the NfL technology, Memorial Healthcare is investing nearly $30 million in a new facility that will specialize in neurology and orthopedics and will also house a health and wellness center for the community.

For more information about Memorial Healthcare, its Institute for Neurosciences and Multiple Sclerosis or the neurofilament light chain (NfL) research study, visit or call 989-723-1390.

Concepts Keywords
Algorithm Differences standardized algorithm
Alzheimer Mischer Neuroscience Institute
Biomarkers Multiple sclerosis
Blood Neurological disorder
Brain Neurology
CEO Branches of biology
Dementia Neurofilament light polypeptide
Disability Biomarkers
Fingerprint MS
Headache Dementia
Hospital Differences standardized algorithm
Michigan Hospital based services
Molecule Prospectively multiple sclerosis
Multiple Sclerosis
Muscular Dystrophies
Nerve
Nerve Cells
Neurofilament
Neurological
Neurologist
Neurology
NfL
Ophthalmologic
Orthopedics
OWOSSO
Pain
Polypeptide
Reproducibility
Shiawassee County
Spinal Cord
Spinal Fluid
Stroke
Vestibular

Semantics

Type Source Name
disease MESH stroke
disease DOID stroke
disease MESH Muscular dystrophies
disease MESH community
gene UNIPROT TNFRSF19
disease DOID dementia
disease MESH dementia
disease MESH development
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT TNFSF14
gene UNIPROT CHL1
disease MESH emergency
gene UNIPROT IMPACT
gene UNIPROT MAGEE1
gene UNIPROT NEFL

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *